E N D
Supplementary Figure 1 AAATACAAAGCAGCTCTGTGGGTTCCACTGGTTTGCAGCCTCTGATCTAATTTCTAAAGTGGGTGTAGCAGGTTTTTAACCTGTAAATTATGGTGATCGGCAGGTCAGGGTAAATGGTAGTTGTGTGTGGGGAAGAGATGATGGCAACAGATGTTTTCCTCCTGCAAAAACTAAAATGTGGGAGTGACTTCTCTGGCCATGACTCCATGGTCTCTCCCCTCAGAGCCATTTTCAGTAAAATTTTTATAGTTTAAAAAATACGGTTCTGAACAATTTTTGTTAGAGTTATTTTGGGATTTTTAAATAGTTTTTTGGTTGTGTATATGGTAGAATTCTTAAAATTATACAATTATAATGTATAAAAAAGCATGCAATTATAATTCATAAAATTATAGCCCCACTGACCATTCTCCTGTAGCTGGGAGCAGTTCACACTAACAGGGCTATACCCCCATGCTGACCTGCTCTGCAGGATCCCAGGAAGGTGAGCATAGCCTACTAACCTGTTTGGGTAGCACAGCGACAGCAACTGAGGCCTTGAAGGCTGTTATCAGAAAATTGTGGGCGGAAACTTCCAGGGGTTTGCTCTGAGCTTCTTGAGGCTTCTCAGCTTCAGCTGCAAAGTGAGTGGGTGTTTCTTTGAGAAGCAGAATCAGAGAGAGAGAGATAGAGAAAGAGAAAGACAGAGGTGTTTCCCTTAGCTATGGAAACTCTATAAGAGAGATCCAGCTTGCCTCCTCTTGAGCAGTCAGCAACAGGGTCCCGTCCTTGACACCTCAGCCTCTACAGGACTGAGAAGAAGTAAAACCGTTTGCTGGGGCTGGCCTGACTCACCAGCTGCCATGCAGCAGCCCTTCAATTACCCATATCCCCAGATCTACTGGGTGGACAGCAGTGCCAGCTCTCCCTGGGCCCCTCCAGGCACAGTTCTTCCCTGTCCAACCTCTGTGCCCAGAAGGCCTGGTCAAAGGAGGCCACCACCACCACCGCCACCGCCACCA CpG1 CpG2
Supplementary Figure 2 b a Overall survival 1.0 0.8 0.6 0.4 0.2 0 rRT+APG101 rRT rRT+APG101 rRT HR=0.38 [0.12-1.19] p>0.05 HR=5.4 [1.73-16.9] P=0.0023 Survival Probability 0 200 400 600 800 Time [days] 0 250 500 750 1000 1250 Time [days] CD95L meth high CD95L methlow
Supplementary Figure 3 a b Progression-freesurvival CD95L + CD95L - 1.0 0.8 0.6 0.4 0.2 0 1.0 0.8 0.6 0.4 0.2 0 Overall survival CD95L - CD95L + rRT+APG101 rRT rRT+APG101 rRT rRT+APG101 rRT rRT+APG101 rRT Progression-free Survival [%] Progression-free Survival [%] 0 2 4 6 8 10 12 14 16 Time [months] 0 2 4 6 8 10 12 14 16 Time [months] c d Overall survival 1.0 0.8 0.6 0.4 0.2 0 1.0 0.8 0.6 0.4 0.2 0 Overall Survival [%] Overall Survival [%] 0 10 20 30 40 Time [months] 0 10 20 30 40 Time [months]
Supplementary Figure 4 a Cox regression for cg10161121 Cox regression for cg06983746
b Cox regression for cg10161121 RT TMZ Cox regression for cg06983746 RT TMZ